In its full-year 2024 financial results and business update, Entera Bio Ltd. (NASDAQ: ENTX) announced a significant year of growth and transformation. The company, which leads in the development of oral peptides and proteins replacement therapies, reported key business achievements and financial results for the year. They advanced their oral peptide PTH(1-34), GLP1/Glucagon, and GLP2 tablet programs, significantly increased shareholder value, and strengthened their balance sheet.

Phillip Frost, the CEO and Chairman of OPKO Health, Inc., has bought 100,000 shares of common stock in the company. The purchase averaged $1.6485 per share, amounting to a total of $164,850. The transaction was closely aligned with the current market value of $1.66 per share. This acquisition indicates Frost's confidence in the company, which currently maintains a healthy liquidity position with a current ratio of 3.43.

OPKO Health and Entera Bio have entered into a partnership to progress an oral GLP-1/Glucagon dual agonist tablet into clinical trials. This tablet will be used for the treatment of obesity and metabolic disorders. The collaboration aims to make advancements in the medical field and develop solutions for these health issues.

This report discusses a collaboration and license agreement between Entera Bio Ltd. and OPKO Health, Inc., along with OPKO Biologics Ltd. The collaboration aims to develop and make decisions about the oral delivery of a dual agonist GLP-1/glucagon peptide using Entera's N-Tab technology platform. The treatment is intended for obesity, metabolic and fibrotic disorders in humans. The program incorporates OPKO's proprietary long-acting oxyntomodulin.

1) Brief Summary: Entera Bio Ltd has shown a significant year-on-year sales growth of 607.14%, however, the company's performance in the past month and quarter is negative with -15.15% and -22.94% respectively. The company's ROE is significantly negative at -103.34% and its ROI is also negative at -116.61%. This indicates that the company is not generating a positive return on its investments and shareholders' equity. The company's recent insider transactions show the awarding of shares and stock options to various directors in lieu of cash payments, indicating possible cash flow issues. The company also shows a negative net cash flow of $-2,345,000.0 both in its TTM 2024 and FY 2024 financials. 2) MARKET_SCORE: Given the negative performance metrics and potential cash flow issues, the likelihood of an upward move is low. MARKET_SCORE: 40

3) PRICE_TARGET: The company's financial fundamentals and recent performance do not justify a significant rise in price in the short term. Therefore, the price target remains close to the current price. PRICE_TARGET: $1.80

4) AI_RPT_HEADLINE: "Entera Bio's Growth Shadowed by Negative Performance and Cash Flow Woes."

As a financial analyst, it would be hard to pinpoint one single type of additional data that could improve my confidence as it largely depends on the context and the nature of the analysis. However, generally, X6 - More financial metrics could be a good choice. More detailed and comprehensive financial data allows for a more in-depth and accurate analysis of a company's performance, financial health, and potential risks. This could include data on cash flow, debt levels, profitability, efficiency ratios, and other relevant financial

====================================================== : 2025-04-02 18:20:58

# Analysis Completed Elapsed Time: 35.18 seconds